The life-threatening disease has no cure and, until now, no known treatment.
The clinical trial of the drug -- called sirolimus -- was the first randomized, controlled study designed to develop a therapy for the lung disease, lymphangioleiomyomatosis, or LAM.
LAM is a progressive, cystic lung disease that occurs almost exclusively in women. In LAM, smooth muscle cells grow uncontrollably and spread to restricted areas in the body, including the lungs, lymph nodes and vessels and kidneys, limiting the flow of air, blood and immune system fluid, or lymph.
Shortness of breath and recurrent lung collapse are common in patients with LAM; until now, lung transplantation has been the only hope for patients who progress to respiratory failure. LAM affects about five per million people.
The positive results from the clinical trial of sirolimus, also known as rapamycin, were reported last month in the online edition of the New England Journal of Medicine.
The lead investigators in the study were from the University of Cincinnati and Cincinnati Children's Hospital Medical Center. Alan Barker, M.D., an OHSU expert in rare lung diseases, was a principal investigator in the study.
The study was conducted at 13 institutions throughout the United States, Canada and Japan. The only West Coast institutions involved in the study were OHSU and the University of California at Los Angeles. Research subjects from the Northwest and northern California were enrolled in the study at OHSU.
Eighty-nine women with LAM, aged 18 or older, participated in the study. Some were treated with sirolimus; others were given a placebo.
The researchers found that sirolimus stabilized lung function and was associated with improvement in measures of functional performance and quality of life.
OHSU's Barker said that the study results point to a potential treatment for LAM. The results are also important because they could serve as a model for treating common types of cancers.
"Like cancer, LAM occurs when cells grow out of control; in LAM's case, cells in the blood vessels and breathing passages in the lung grow out of control," Barker said. “This drug stopped that abnormal growth of cells."
Barker said that OHSU also will be part of a follow-up study that examines the effectiveness of another drug in treating LAM.
The sirolimus study was funded by the National Institutes of Health's Office of Rare Disease Research; the Food and Drug Administration; the LAM Foundation; the Japanese Ministry of Health, Labour and Welfare; the Canadian Institutes of Health Research; Cincinnati Children’s Hospital, the University of Cincinnati; the Tuberous Sclerosis Alliance Rothberg Courage Award; and Vi and John Adler and the Adler Foundation.
Pfizer, maker of sirolimus, provided the drug and financial support but had no role in study design, conduct, analysis or reporting.About OHSU
Todd Murphy | EurekAlert!
New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia
New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
17.08.2017 | Physics and Astronomy
17.08.2017 | Materials Sciences
17.08.2017 | Materials Sciences